Ctep P9466 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.

United statesAnita giobbie hurderZeynep erogluGenentech rocheBoehringer ingelheimDepartment of oncologic sciencesCutaneous oncologyMoffitt cancer centerOncologic sciencesSouth florida morsani collegeAsco annual meetingCtep p9466